• 생물치료정신의학
• /
• 제24권3호
• /
• pp.142-155
• /
• 2018

Insomnia in patients with hematopoietic stem cell transplantation(HSCT) has been underdiagnosed and undertreated. This study reviewed the frequency, characteristics, physical and psychological effects, and treatments of insomnia in HSCT patients to highlight clinical importance in this specialized population. Furthermore, the authors intended to suggest a model that would conceptualize insomnia in the context of HSCT. In the pre-transplant period, about half of patients with HSCT suffered from sleep disturbance. A substantial number of patients experienced distressing insomnia during the HSCT procedure and recovered to the level of the pre-transplant period. However, sleep disruption could be a chronic symptom in HSCT survivors and could negatively impact quality of control, cancer-related fatigue(CRF), immune function, and psychological distress. The 3P's model(Predisposing, Precipitating, Perpetuating) explains insomnia in cancer population and could be also relevant to HSCT patients with specific consideration of CRF, graft-versus-host diseases, specific properties of hematological disease, and protective isolated milieu. Effective treatment of insomnia in HSCT includes non-pharmacological(e.g., cognitive behavioral therapy, environmental modification) and pharmacological interventions. The decision of pharmacological treatment should be based on the issue of safety due to high risk of potential drug-drug interactions. Screening, treatment, and further research of insomnia in HSCT patients using validated subjective and/or objective measures are warranted.

• 한국분말재료학회지
• /
• 제25권6호
• /
• pp.459-465
• /
• 2018

Most commercially available detonation nanodiamonds (DNDs) require further processing to qualify for use in biomedical applications, as they often contain many impurities and exhibit poor dispersibility in aqueous media. In this work, DNDs are modified to improve purity and impart a high colloidal stability to the particles. The dispersive and adsorption properties of modified DNDs are evaluated in terms of the suitability of DNDs as carriers for non-steroidal anti-inflammatory drugs (NSAIDs) in transdermal delivery. The study of adsorption on strongly positively and strongly negatively charged DNDs showed their high loading capacity for NSAIDs, and a pronounced relationship between the drugs and the particles' charges. Experiments on long-term desorption carried out with DND/NSAID complexes indicate that the nanoparticles exert a sustained effect on the drug release process.

• KSBB Journal
• /
• 제22권4호
• /
• pp.260-264
• /
• 2007

본 실험에서는 마이크로어레이 형태로 펩타이드와의 공유결합에 의한 고정화를 시키기 위해 유리 칩의 표면을 아민기에서 thiol기로 개질하였다. 펩타이드의 lysine기와 thiol기와의 공유결합반응에는 12시간 정도의 반응시간이 필요하였고 실온보다는 35$^{\circ}C$가 유리함을 확인하였다. Trypsin-FITC와의 반응을 통해 trypsin 결합부위를 가진 target 펩타이드가 control 펩타이드보다 더 높은 형광 신호를 나타냄을 확인하였고, 이를 통해 target 펩타이드를 마이크로어레이 상에서 식별할 수 있었다. 이 trypsin-FITC와의 결합 친화도 차이를 별도의 QCM 실험을 통해서도 확인하였다. 또한 작은 부피의 spot과 높은 농도의 펩타이드 용액이 더욱 높은 표면형광신호를 생성함을 확인하였다. 본 실험을 통해 펩타이드 마이크로어레이 칩 개발을 위한 기초 조건을 확립하였다.

• 공업화학
• /
• 제28권4호
• /
• pp.404-409
• /
• 2017

천연고분자 키토산은 생체적합하고 생분해성의 특성뿐만 아니라 항암, 항균, 콜레스테롤 저하 등의 다양한 생체활성을 갖고 있어 의료용 분야에서 많이 응용되고 있다. 현재 키토산을 약물전달시스템에 응용한 다양한 약물이 담지 된 키토산 나노입자를 개발하여 질병을 치료할 수 있는 연구가 활발히 진행 중에 있다. 키토산에 존재하는 free 아민($-NH_2$) 그룹은 다양한 소수성기를 물리적 화학적 개질을 통해 결합이 가능하며 소수성기가 도입된 키토산은 물에 분산시 자기회합에 의한 shell-core 나노입자를 형성하고 core 부분에 다양한 난용성 약물을 담지하여 물에 대한 용해도를 증가시킬 수 있으며, 단백질, 항암제, 백신 등의 다양한 약물을 담지하여 기존 약물의 부작용을 최소화하여 치료효과를 극대화할 수 있다. 또한, 키토산에 도입된 소수성기에 따라 입자의 크기 및 방출 속도를 제어할 수 있어 다양한 의료용 분야에 응용이 가능하다. 본 총설에서는 다양한 소수성기가 도입된 키토산 나노입자의 제조 및 특성과 특성에 따른 약물전달시스템의 응용성에 관하여 논의 하고자 한다.

• Journal of Pharmaceutical Investigation
• /
• 제6권3호
• /
• pp.48-57
• /
• 1976

An enhancement in the dissolution rate of the drug should facilitate its GI absorption if the absorption process is dissolution rate limited. One of the need for the techniques that can potentially enhance the dissolution rate and extent of absorption of hydrophobic drugs is the formation of coprecipitates with pharmacologically inert, polymeric materials. The physicochemical modification offers the advantage of possibly enabling one to administer the drug orally in a form from which it is most available for GI absorption. Several $investigation^{1-15)}$ demonstrated that the formation of solid dispersions or coprecipitates of relatively water-insoluble drugs with various pharmacologically inert carriers can increase singnificantly their in vitro dissolution rates. However, little information is available in the literature related to the dissolution rate patterns of furosemide, a water-insoluble diurectices, with respect to the sort of copolymer and the ratio of coprecipitates as a function of time, respectively. The purpose of the present investigation was to ascertain, the general applicability of the copolymers to use fore more fast, enhanced dissolution techniques of furosemide. To accomplish the need for enhancement in the dissolution rate of furosemide, varying ratio coprecipitates with different water-soluble polymers, such as polyvinylpyrrolidone (PVP), polyethylene glycol 4000(PEG 4000), and polyethylene glycol 6000 (PEG 6000), were quantitatively studied by comparing their dissolution characteristics of furosemide. The dissolution patterns of pure furosemide, varying ratio furosemide-PVP coprecipitates, (1:2, 1:5, and 1:9(w/w)), furosemide-PEG 4000 coprecipitates (1:4, 1:9, and 1:19(w/w), furosemide-PEG 6000 coprecipitates(1:4, 1:9, and 1:19(w/w)), and the same ratio physical mixtures, respectively, were compared by the amount dissolved as a function of time.

• 공업화학
• /
• 제19권5호
• /
• pp.457-465
• /
• 2008

인간의 질병을 치료하기 위한 여러 가지 의료 시스템의 개발이 생명공학의 발전과 함께 많은 연구가 이루어지고 있다. 또한 약물이나 유전자와 같은 생리활성물질을 체내에 안전하게 전달할 수 있는 시스템의 개발과 함께 이루어지고 있다. 이러한 시스템에 있어서 가장 중요한 것은 생체적합성 및 생체분해성 그리고 무독성의 특성을 가진 생체의료용 고분자를 개발하는 것이다. 천연고분자물질인 키토산은 좋은 생체적합성과 생체활성의 특성을 가지고 있어서 생체의료용 재료로 심도 있게 고려되어지고 있다. 키토산의 물성은 키틴의 결정성 구조에 따라 다르게 설명되므로 키틴의 구조적 분석에 대한 연구가 생체재료로써의 응용을 위해서 선행되어야 한다. 이러한 관점에서 본 총설에서는 키틴의 결정성 구조 분석, 키토산의 일반적인 물성 그리고 생체의료용 재료로써 저분자량 수용성 키토산의 가능성을 소개하였다. 또한 다양한 기능성기를 이용한 저분자량 수용성 키토산의 화학적인 개질을 약물전달체로써의 가능성을 강조하고 생체이용율의 향상을 위해 수행하였다.

• 대한화장품학회지
• /
• 제43권2호
• /
• pp.165-174
• /
• 2017

이 연구는 소수성 폴리락타이드(PLA) 블록과 친수성 하이퍼브랜치드 폴리글리세롤(hbPG) 블록으로 구성된 양친매성 블록 공중합체(PLA-b-hbPG)의 합성방법에 대한 것이다. 또한, hbPG 블록을 4-hydroxyl cinnamic acid (CA)로 에스터 반응화하여, 광가교가 가능한 블록 공중합체인 PLA-b-hbPG-CA에 대한 접근법에 대해서도 보고하였다. 연구된 양친성 고분자는 친수기에 많은 양으로 존재하는 폴리글리세롤에 의해 화장품용 약물 전달체로 사용이 가능한 작은 크기(100 nm)의 마이셀을 형성함을 확인하였다. 또한, hbPG으로 구성된 마이셀의 corona 부분은 우수한 친수성을 나타내어 생체 내 독성을 최소화할 수 있음을 확인하였다. 소수성 활성성분이 담지된 PLA-b-hbPG-CA 마이셀은 생체적합성 및 자기조립구조에 의해 화장품용 약물 전달체로 활용이 가능할 것으로 기대된다.

• 생체재료학회지
• /
• 제22권4호
• /
• pp.303-310
• /
• 2018

Background: Photodynamic therapy (PDT) is photo-treatment of malignant or benign diseases using photosensitizing agents, light, and oxygen which generates cytotoxic reactive oxygens and induces tumour regressions. Several photodynamic treatments have been extensively studied and the photosensitizers (PS) are key to their biological efficacy, while laser and oxygen allow to appropriate and flexible delivery for treatment of diseases. Introduction: In presence of oxygen and the specific light triggering, PS is activated from its ground state into an excited singlet state, generates reactive oxygen species (ROS) and induces apoptosis of cancer tissues. Those PS can be divided by its specific efficiency of ROS generation, absorption wavelength and chemical structure. Main body: Up to dates, several PS were approved for clinical applications or under clinical trials. $Photofrin^{(R)}$ is the first clinically approved photosensitizer for the treatment of cancer. The second generation of PS, Porfimer sodium ($Photofrin^{(R)}$), Temoporfin ($Foscan^{(R)}$), Motexafin lutetium, Palladium bacteriopheophorbide, $Purlytin^{(R)}$, Verteporfin ($Visudyne{(R)}$), Talaporfin ($Laserphyrin^{(R)}$) are clinically approved or under-clinical trials. Now, third generation of PS, which can dramatically improve cancer-targeting efficiency by chemical modification, nano-delivery system or antibody conjugation, are extensively studied for clinical development. Conclusion: Here, we discuss up-to-date information on FDA-approved photodynamic agents, the clinical benefits of these agents. However, PDT is still dearth for the treatment of diseases in specifically deep tissue cancer. Next generation PS will be addressed in the future for PDT. We also provide clinical unmet need for the design of new photosensitizers.

• Bulletin of the Korean Chemical Society
• /
• 제33권8호
• /
• pp.2597-2602
• /
• 2012

Novel 1,4-substituted piperazine derivatives 5, Series A and B were designed by fragment analysis and molecular modification of 4 selected piperazine-containing compounds which possess antidepressant activity. We synthesized new 39 analogues of Series A and 10 compounds of Series B, respectively. The antidepressant screening against DA, NE, and serotonin neurotransmitter uptake inhibition was carried out using the Neurotransmitter Transporter Uptake Assay Kit. The compounds in Series B showed relatively higher reuptake inhibitory activity for SERT, NET, and DAT than those in Series A. The length of spacer between the central piperazine core and the terminal phenyl ring substituted at the piperazine ring in Series B seems to exert an important role in the activity.

• Biomolecules & Therapeutics
• /
• 제26권6호
• /
• pp.533-538
• /
• 2018

Nitric oxide (NO) mediates various physiological and pathological processes, including cell proliferation, differentiation, and inflammation. Protein S-nitrosylation (SNO), a NO-mediated reversible protein modification, leads to changes in the activity and function of target proteins. Recent findings on protein-protein transnitrosylation reactions (transfer of an NO group from one protein to another) have unveiled the mechanism of NO modulation of specific signaling pathways. The intracellular level of S-nitrosoglutathione (GSNO), a major reactive NO species, is controlled by GSNO reductase (GSNOR), a major regulator of NO/SNO signaling. Increasing number of GSNOR-related studies have shown the important role that denitrosylation plays in cellular NO/SNO homeostasis and human pathophysiology. This review introduces recent evidence of GSNO-mediated NO/SNO signaling depending on GSNOR expression or activity. In addition, the applicability of GSNOR as a target for drug therapy will be discussed in this review.